Management of SGLT2i-associated perioperative ketoacidosis (SAPKA) / Euglycemic Diabetic Ketoacidosis (EDKA).

This infographic reviews the risk of perioperative euglycemic diabetic ketoacidosis (EKDA) associated with sodium-glucose co-transporter 2 inhibitor (SGLT2i), which is more specifically called SGLT2i-associated perioperative ketoacidosis (SAPKA)1. The incidence of SAPKA/perioperative EDKA is estimated to be 0.17 % for nonemergent procedures and 1.1 % for emergent procedures2. The goal is to guide both anesthesia and surgery teams regarding the perioperative management of SGLT2i's to mitigate the risk of SAPKA/EDKA.